Work

Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx371.010

Authors: A.B. Apolo, J. Ellerton, J.R. Infante, M. Agrawal, M.S. Gordon, R. Aljumaily, C.D. Britten, L. Dirix, K-W. Lee, M.H. Taylor, P. Schöffski, D. Wang, A. Ravaud, A. Gelb, J. Xiong, G. Rosen, M.R. Patel

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Nevada Cancer Research Foundation, Sarah Cannon, Tennessee Oncology, HonorHealth, University of Oklahoma Medical Center, Medical University of South Carolina, Seoul National University, Seoul National University Bundang Hospital, Oregon Health & Science University, OHSU Knight Cancer Institute, Universitair Ziekenhuis Leuven, Henry Ford Hospital, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, EMD Serono, Inc. (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Pfizer

OpenAlex ID: W2762013846

FWCI: 2.79

Cites:

Cited by: 17

Related to: 10